A Multicenter, Open-Label, Extension Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults With Growth Hormone Deficiency
Latest Information Update: 22 Jan 2025
At a glance
- Drugs Lonapegsomatropin (Primary)
- Indications Somatotropin deficiency
- Focus Adverse reactions
- Sponsors Ascendis Pharma
Most Recent Events
- 17 Jan 2025 Status changed from active, no longer recruiting to completed.
- 27 Dec 2023 Status changed from recruiting to active, no longer recruiting.
- 03 Jan 2022 New trial record